Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIOCIUS and Agilent Launch High-throughput, RapidFire® Mass Solution for Drug Discovery

Published: Friday, May 21, 2010
Last Updated: Friday, May 21, 2010
Bookmark and Share
Advanced, integrated system for high quality in vitro ADME analysis unveiled at ASMS Conference, May 23-May 27.

BIOCIUS Life Sciences, Inc. and Agilent Technologies Inc. have announced the launch of the RF360 High Resolution System for high-throughput screening of in vitro ADME assays.

Combining the mass capabilities of Agilent’s time-of-flight (TOF) mass spectrometers and the unprecedented sample processing speed of RapidFire® technology, the instrument in vitro ADME analysis by eliminating the method development bottleneck in drug discovery.

The latest addition to the RapidFire portfolio, the RF360 High Resolution system, will be on display in the BIOCIUS hospitality suite at the 58th Annual American Society for Mass Spectrometry Conference in Salt Lake City, Utah from May 23rd to May 27th.

“High resolution mass spectrometry coupled with the unparalleled sample preparation throughput of the RapidFire platform enables significant streamlining of in vitro ADME assays,” said Can ‘Jon’ Ozbal, Chief Operating Officer of BIOCIUS. “Extending our partnership with Agilent Technologies, the leader in TOF mass spectrometry allows us to completely eliminate the bottleneck of developing test-compound specific mass spectrometry methods.” This revolutionary approach to in vitro ADME has been demonstrated to reduce analysis time to a fraction of that of conventional methods while requiring a minimal amount of operator input.

RapidFire technology combined with TOF mass spectrometers enables a wide range of ADME assays, including drug-drug interaction, metabolic stability, Caco, PAMPA and others. When performing such assays with the RF360, a priori knowledge of the test compound is not required, as data is acquired in full scan TOF-MS mode. Post acquisition, the relevant data is extracted using RapidFire software, eliminating the time consuming and labor-intensive steps of LC/MS method development and batch analysis.

“Only TOF spectrometry can meet the scan speed and resolution demands required for these high-throughput types of applications,” said Gustavo Salem, vice president and general manager of Agilent’s Biological Systems Division. “Partnering with BIOCIUS on the RF360 has provided a solution that is the fastest approach to ADME on the market.”

Representatives from BIOCIUS and Agilent will be at the ASMS Conference at booth numbers 67 and 68, respectively. The RF360 High Resolution System will be on display in BIOCIUS Hospitality suite, 251A, at the Salt Palace Convention Center. Additionally oral and poster presentations will feature the instrumentation:

ORAL PRESENTATION:

Session: Increasing Throughput for ADME and PK Assays

8:50 a.m., Monday, June 24th, Hall 2

Reducing Bottlenecks in ADME Sample Analysis using Solid Phase Extraction with a Quadrupole Time-of-Flight Mass Spectrometer. Panos Hatsis, Michelle Romm, Vaughn Miller, Jakal Amin, William A. LaMarr, Can “Jon” Ozbal, Shawn Harriman. Novartis Institutes for Biomedical Research, Cambridge, MA; BIOCIUS Lifesciences, Woburn, MA

POSTERS:

1. Session: TP21, Drug Metabolism: High Throughput

Number: 498, Tuesday June 25th

Evaluation of Accurate Mass TOF-MS for Use in High Throughput PAMPA Screening. Michelle Romm, Nikunj Parikh, Vaughn Miller, William A. LaMarr, Can “Jon” Ozbal. BIOCIUS Life Sciences, Inc., Woburn, MA

2. Session: TP21, Drug Metabolism: High Throughput Time

Number: 500, Tuesday June 25th

Comparison of LC/MS/MS and a Fully Integrated Autosampler/Solid Phase Extraction System for the Analysis of Permeability Samples. Adam C Amaral, Christopher Caldwell, Panos Hatsis, Jakal Amin, Shawn Harriman. Novartis, Cambridge, MA

3. Session: ThP24, High Throughput Analysis/Robotics

Number: 572, Thursday, June 27th.

Development of a High-Throughput MS-Based Bioanalytical Method for Assessment of P-Glycoprotein Inhibition Andrew Wagner, Janet Kolb, John Herbst, Tatyana Zvyaga, Conway Charlie, Harold Weller, Wilson Shou, Can “Jon” Ozbal. Bristol-Myers Squibb Company, Wallingford, CT; Bristol-Myers Squibb Company, Princeton, NJ; BIOCIUS Life Sciences, Inc, Woburn, MA.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Collaborating with Florida International University
Collaboration to further advance the identification and characterization of designer drugs.
Tuesday, February 26, 2013
Agilent Technologies and Ameritox Form Collaboration
Agilent Technologies Inc. and AmeritoxSM announced that they have formed a research collaboration that could accelerate analysis in the field of medication monitoring.
Tuesday, February 12, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Technologies Reports Second-Quarter 2012 Results
Third-quarter fiscal year 2012 revenue guidance of $1.77 billion - $1.79 billion and non-GAAP earnings guidance of $0.82 - $0.84 per share.
Wednesday, May 16, 2012
Agilent and Integrated Diagnostics Enter Strategic Partnership
The partnership will develop protein-based assays for early disease detection.
Wednesday, January 11, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Agilent Technologies and A*STAR’s ETC Launch All-in-One Drug-Screening Platform at Singapore Screening Centre
Agilent to provide a full spectrum of automation technologies to biomedical researchers, enabling highly efficient drug screening in one location.
Tuesday, August 02, 2011
Scientific News
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
The Need for Speed
Evaluating MALDI-TOF as a high-throughput screening technology for the pharmaceutical industry.
Antarctic Sponge Extract Kills MRSA
New findings may provide opportunity for developing new drugs to fight dangerous bacteria currently highly resistant to treatment.
US-India Collab Finds Molecular Signatures of Severe Malaria
Study may be a significant advancement in understanding the causes of severe malaria.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
Gene Expression Controls Revealed
Researchers have modelled every atom in a key part of the process for switching on genes, revealing a whole new area for potential drug targets.
An Old-New Weapon Against Emerging Chikungunya Virus
Researchers utilize existing drugs to interfere with host factors required for replication of Chikungunya virus.
Using Gene-editing Technology for Faster, Cheaper Antiviral Drug Development
UCLA scientists are working to develop special screening libraries based on a gene-editing technology called CRISPR.
Can Gender Play A Role In Determining Cancer Treatment Choices?
MD Anderson study reveals “sex-biased” gene signatures in review of 13 cancer types.
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!